- Home
- ALXO vs NRXP Comparison
ALXO vs NRXP Comparison
Compare ALXO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 151.1M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALXO | NRXP |
|---|---|---|
| Price | $1.24 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $4.60 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 1.5M | 699.8K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.36 | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,507.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $1.65 |
| 52 Week High | $2.66 | $5.06 |
Technical Indicators
Market Signals| Indicator | ALXO | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 29.11 |
| Support Level | $0.86 | $1.68 |
| Resistance Level | $1.30 | $2.49 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 81.20 | 20.95 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.